From: Using public clinical trial reports to probe non-experimental causal inference methods
Adverse Event (ICD10) | Drug A (ATC) | Drug B (ATC) | Clinical Trial NCTs | Contingency Table | Denoised Odds Ratio |
---|---|---|---|---|---|
Hiccups (R06.6) | Nicotine (N07BA01) | Bupropion (N06AX12) | 332644 | \(\left[ \begin{array}{rr} 0 &{} 264 \\ 35 &{} 225 \\ \end{array}\right]\) | 58.63 |
Dry Mouth (K11.7) | Bupropion (N06AX12) | Nicotine (N07BA01) | 332644 | \(\left[ \begin{array}{rr} 0 &{} 260 \\ 20 &{} 244 \\ \end{array}\right]\) | 27.30 |
Conjunctivitis (H10) | Brimonidine (D11AX21) | Brinzolamide (S01EC04) | 1297920 | \(\left[ \begin{array}{rr} 0 &{} 234 \\ 15 &{} 220 \\ \end{array}\right]\) | 15.56 |
Nausea (R11.0) | Dulaglutide (A10BJ05) | Glimepiride (A10BB12) | 1644500 | \(\left[ \begin{array}{rr} 1 &{} 242 \\ 25 &{} 219 \\ \end{array}\right]\) | 12.82 |
Dysgeusia (R43.2) | Brinzolamide (S01EC04) | Brimonidine (D11AX21) | 1297920 1297517 | \(\left[ \begin{array}{rr} 2 &{} 453 \\ 38 &{} 422 \\ \end{array}\right]\) | 11.02 |
Heartburn (R12) | Nicotine (N07BA01) | Bupropion (N06AX12) | 332644 | \(\left[ \begin{array}{rr} 2 &{} 262 \\ 31 &{} 229 \\ \end{array}\right]\) | 8.52 |
Vomiting (R11.1) | Dulaglutide (A10BJ05) | Glimepiride (A10BB12) | 1644500 | \(\left[ \begin{array}{rr} 1 &{} 242 \\ 19 &{} 225 \\ \end{array}\right]\) | 7.60 |
Hypoglycaemia (E16.2) | Glipizide (A10BB07) | Sitagliptin (A10BH01) | 86515 94770 509262 | \(\left[ \begin{array}{rr} 61 &{} 1201 \\ 279 &{} 754 \\ \end{array}\right]\) | 7.10 |
Dysgeusia (R43.2) | Telavancin (J01XA03) | Vancomycin (A07AA09) | 107978 91819 | \(\left[ \begin{array}{rr} 62 &{} 876 \\ 311 &{} 618 \\ \end{array}\right]\) | 7.06 |
Nausea (R11.0) | Tigecycline (J01AA12) | Ertapenem (J01DH03) | 366249 | \(\left[ \begin{array}{rr}46 &{} 462 \\ 233 &{} 320 \\ \end{array}\right]\) | 6.97 |